Table 1.
Baseline characteristics and immunological results 2 weeks after the second dose (d35) of the mRNA BNT162b2 vaccine in relation to chronic lymphocytic leukemia patient subgroup and healthy controls.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.